Valeant bulks up PR muscle | Reuters
Valeant, under mounting pressure from Congress and prosecutors over its drug pricing, has hired an attorney in Washington and crisis public relations experts with political connections, according to sources familiar with the matter.
Outsourcing of CRNAs part of larger industry trend | Crain’s Detroit Business
A contentious move to outsource certified registered nurse-anesthetists at St. John Health System is just part of a larger trend among healthcare providers in Southeast Michigan and elsewhere to contract the management of various specialists.
Eleventh-hour deal keeps Ga. hospital open | The Chattanoogan
An agreement was reached at the last minute on Monday to keep Hutcheson Medical Center in Fort Oglethorpe open. ValorBridge, which will pay $4.2 million for the facility, is affiliated with ApolloMD.
AstraZeneca explores deal with Acerta for cancer drug | Bloomberg.com
AstraZeneca said it’s exploring a deal with Acerta Pharma that would give the U.K. drugmaker a potential blockbuster medicine for blood cancers as well as diseases in which the body attacks itself.
Angry investors say Ocata Therapeutics undervalued in sale | Boston Globe
Executives struck a triumphant tone last month when Ocata Therapeutics, Marlborough, Mass., said it had agreed to be sold to the Japanese drugmaker Astellas Pharma, in a $379 million deal that promised a nearly 80% premium over Ocata’s share price. But shareholders at Ocata, a 21-year-old biotech long seen as a pioneer in the emerging field of regenerative medicine, have reacted to the buyout with bitter disappointment.
